Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

NewLink Genetics Corp (NASDAQ:NLNK)

During the Trading Day
52.15 +0.99 / +1.94%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
52.80 +0.65 / +1.25%
Volume: 6.2K
Health Technology

Company Description

NewLink Genetics Corp. is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.

Contact Information

NewLink Genetics Corp.
2503 South Loop Drive
Ames Iowa 50010
P:(515) 296-5555
Investor Relations:



Mutual fund holders28.55%
Individual stakeholders27.84%
Other institutional22.59%

Top Executives

Charles J. LinkChairman, Chief Executive & Scientific Officer
Nicholas N. VahanianPresident & Chief Medical Officer
John B. HennemanChief Financial Officer, Secretary & Executive VP
W. Jay RamseyChief Clinical & Compliance Officer
Brian WileyVice President-Business Development